BioView Ltd.

As of June 30, 2023, BioView Ltd. carries a market capitalization of 4.88B, placing it among publicly traded companies globally. Its enterprise value stands at 3.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2023, BioView Ltd. has 135,512.85 shares outstanding.

These figures are as of June 30, 2023.

As of June 30, 2023, BioView Ltd. maintains a current ratio of 3.10, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2023.

Over the twelve months ended June 30, 2023, BioView Ltd. recorded 22.20M in income tax expense.

As of the close on October 22, 2026, BioView Ltd.'s stock has declined approximately 74.74% over the past 52 weeks. The 50-day moving average sits at 7,652.24, while the 200-day moving average is 12,640.46.

As of June 30, 2023, BioView Ltd. holds 1.85B in cash and equivalents against 397.00M in total debt, resulting in a net debt position of -1.85B. Total book value stands at 2.88B, with working capital of 2.13B providing operational flexibility.

These figures cover the twelve months ended June 30, 2023.

BioView Ltd.'s most recent stock split took place on October 5, 2026 with a 100:1 split ratio.